儿童神经母细胞瘤影像基因组学:基于CT的影像组学特征预测MYCN扩增
本研究纳入78例儿童神经母细胞瘤患者(训练集55例、测试集23例),从三期CT图像手动勾画的感兴趣区自动提取影像组学特征,构建影像组学特征及联合临床因素的列线图,用于预测MYCN扩增。联合列线图预测性能优于单纯临床模型(训练集AUC 0.95 vs 0.82,测试集AUC 0.91 vs 0.70),决策曲线分析证实其临床效用。
要点
- 基于CT的影像组学特征可预测儿童神经母细胞瘤MYCN扩增。
- 影像组学特征联合临床因素的列线图预测MYCN扩增优于单纯临床模型。
- 增强前后的CT图像对预测MYCN扩增均有价值。
核心结论
- 所构建的基于CT的影像组学特征能够预测MYCN扩增。
- 影像组学特征联合临床因素预测MYCN扩增的性能优于单纯临床模型(训练集AUC 0.95 vs 0.82,测试集AUC 0.91 vs 0.70)。
研究设计与样本
- 本研究纳入78例儿童神经母细胞瘤患者,其中训练集55例、测试集23例。
- 从三期CT图像上手动勾画的感兴趣区自动提取影像组学特征,保留筛选后的特征构建影像组学特征,并基于该特征公式计算影像组学评分。
- 临床模型基于临床病理数据和CT图像特征等临床因素建立;联合列线图纳入影像组学特征和临床因素。
- 预测性能采用受试者工作特征曲线分析和决策曲线分析评估。
诊断标准与关键数值
- 影像组学特征由7个筛选出的影像组学特征构建。
- 临床影像组学列线图基于影像组学特征和两个临床因素构建。
- 训练集AUC:临床影像组学列线图0.95 vs 单纯临床模型0.82。
- 测试集AUC:临床影像组学列线图0.91 vs 单纯临床模型0.70。
- 决策曲线分析证实临床影像组学列线图的临床效用。
临床应用与阅片要点
- 增强前后的CT图像对预测MYCN扩增均有价值。
- 将影像组学特征与临床因素关联可提高MYCN扩增的预测性能,优于单纯临床模型。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To construct a CT-based radiomics signature and assess its performance in predicting MYCN amplification (MNA) in pediatric patients with neuroblastoma.
METHODS: Seventy-eight pediatric patients with neuroblastoma were recruited (55 in training cohort and 23 in test cohort). Radiomics features were extracted automatically from the region of interest (ROI) manually delineated on the three-phase computed tomography (CT) images. Selected radiomics features were retained to construct radiomics signature and a radiomics score (rad-score) was calculated by using the radiomics signature-based formula. A clinical model was established with clinical factors, including clinicopathological data, and CT image features. A combined nomogram was developed with the incorporation of a radiomics signature and clinical factors. The predictive performance was assessed by receiver operating characteristics curve (ROC) analysis and decision curve analysis (DCA).
RESULTS: The radiomics signature was constructed using 7 selected radiomics features. The clinical radiomics nomogram, which was based on the radiomics signature and two clinical factors, showed superior predictive performance compared with the clinical model alone (area under the curve (AUC) in the training cohort: 0.95 vs. 0.82, the test cohort: 0.91 vs. 0.70). The clinical utility of clinical radiomics nomogram was confirmed by DCA.
CONCLUSIONS: This proposed CT-based radiomics signature was able to predict MNA. Combining the radiomics signature with clinical factors outperformed using clinical model alone for MNA prediction.
KEY POINTS: • A CT-based radiomics signature has the ability to predict MYCN amplification (MNA) in neuroblastoma. • Both pre- and post-contrast CT images are valuable in predicting MNA. • Associating the radiomics signature with clinical factors improved the predictive performance of MNA, compared with clinical model alone.
引用
- Wu H, Wu C, Zheng H, et al. Radiogenomics of neuroblastoma in pediatric patients: CT-based radiomics signature in predicting MYCN amplification. Eur Radiol. 2020. PMID: 33118047. doi:10.1007/s00330-020-07246-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。